The European Medicines Agency opened a public consultation on 13 November 2026 on a revised list of medically important veterinary safety-reporting terms, with comments due by 31 January 2027. The draft would separate the list from its signal-management guideline, making it relevant to research teams maintaining veterinary pharmacovigilance databases, terminology mappings and safety-study records.
EMA proposes a standalone medically important terms list
The 12-page draft, reference EMA/CVMP/PhVWP/220641/2026, would replace Appendix 1 of the veterinary good pharmacovigilance practices signal-management module. EMA explicitly says the separation is intended to make the list easier to update when needed. The proposal therefore concerns both the contents of the list and how that reference document is maintained.
EMA’s Committee for Veterinary Medicinal Products adopted the text for release for consultation on 5 November. Its November meeting highlights record that decision; the draft’s cover supplies the subsequent opening date and exact comment deadline. Release for consultation is the current development. The document remains a draft, with final adoption and coming-into-effect dates left unassigned.
The proposal links preferred terms with species
The list uses VeDDRA preferred terms, abbreviated PTs, and identifies the species for which each entry is medically important. The introduction describes the list as a tool for prioritising signal detection and management. Inclusion can reflect medical importance independently of an established causal association with a veterinary medicinal product. A list entry consequently does not establish that a medicine caused a reported event.
For database and terminology teams, the structure matters: a preferred term and its species designation must be considered together when interpreting the proposed list. The draft’s table has three columns: preferred term, medically important status by species, and a change marker comparing the entry with the previous list. Those markers distinguish unchanged entries, new medically important terms and species, species changes, and deletions.
Examples from the consultation table show the kinds of changes available for scrutiny:
- Abdominal pain: the species designation is equine, marked as a species change.
- Environmental incident: the species field says not applicable, with the entry marked as new.
- Convulsion: marked for deletion from this list because it is covered by the preferred term Seizure.
- Aggression: marked for removal from this list because of insufficient specificity.
These are proposed changes to the medically important list. The table’s deletion marker should not be read as an announcement that a term has been deleted from the entire VeDDRA terminology. EMA also says the comparison column will be removed in the final version, giving consultation respondents a specific opportunity to examine the documented differences now.
A wider signal-management revision has its own timetable
EMA’s VGVP document register places the new list alongside a separate draft revision of the signal-management module. The existing module was first published in November 2021 and has a listed effective date of 28 January 2022. A concept paper consulted on earlier in 2026 described revising it using experience gained with the veterinary medicines framework.
The register describes the revised module as covering scientific and quality aspects of signal management, together with roles, responsibilities and procedures. It lists that consultation as running from 18 September to 18 December 2026. The standalone medically important terms consultation instead closes on 31 January 2027. Institutions contributing to both need to keep the two deadlines separate.
Independent coverage focuses on the consultation opportunity
In its 16 November regulatory brief, Gulfstream Intelligence founder Scott Morvay identified EMA’s veterinary consultations as formal opportunities to comment on pharmacovigilance terminology and analytical-method validation. The terminology proposal is distinct from the separate GL49 consultation on veterinary residue-study methods.
VigiEye’s 15 November analysis likewise highlighted the move from an appendix to a standalone guideline and its relationship with the signal-management module. EMA’s own register provides the separate closing dates. The immediate institutional opportunity is to review and comment on the proposed reference list.
What research teams can examine before 31 January
For universities and research organisations supporting veterinary pharmacovigilance work, the practical implication is a focused review of terminology dependencies. A research data dictionary can identify where preferred terms, species and medically important flags are stored. Comparing those fields with the draft’s change column can reveal whether a local mapping treats a species-specific entry as universal or retains an obsolete cross-reference.
This is an implication of the proposed structure, rather than a new implementation requirement for universities. Teams preparing comments can connect concrete mapping examples with the relevant draft entries. Research offices coordinating those responses can also identify standard operating procedures that cite the existing appendix and distinguish the document reference from the underlying database rule. Keeping that distinction explicit supports data integrity when explaining which list version informed a study record or analysis.
EMA requests comments through its linked template, with the completed form sent to [email protected]. The next dated milestone for this proposal is the close of comments on 31 January 2027. The consultation gives participating institutions a route to raise specific questions about the list’s terminology, species assignments and relationship with signal management before finalisation.
Sources
- European Medicines Agency: Draft guideline on veterinary good pharmacovigilance practices, list of medically important VeDDRA terms, 13 November 2026; checked 2026-11-17.
- European Medicines Agency: Meeting highlights from the CVMP, 3–5 November 2026, November 2026; checked 2026-11-17.
- European Medicines Agency: Veterinary good pharmacovigilance practices, adopted and draft modules, consultation listing first published 13 November 2026; checked 2026-11-17.
- Gulfstream Intelligence: MHRA sets women’s health agenda, EMA opens veterinary consultations, 16 November 2026; checked 2026-11-17.
- VigiEye: EMA consults on medically important VeDDRA terms to anchor veterinary signal management, 15 November 2026; checked 2026-11-17.







